Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer Darshi et al. Am J Nephrol 2016;44:92-103 (DOI:10.1159/000447954) Table 1. A comparison of GC-MS, LC-MS and NMR technologies in metabolomics
Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer Darshi et al. Am J Nephrol 2016;44:92-103 (DOI:10.1159/000447954) Table 2. Summary of metabolites affected in DKD identified by clinical metabolomic analysis
Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer Darshi et al. Am J Nephrol 2016;44:92-103 (DOI:10.1159/000447954) Table 3. Summary of metabolomic alterations in animal models of DKD
Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer Darshi et al. Am J Nephrol 2016;44:92-103 (DOI:10.1159/000447954) Fig. 1. Overview of urinary metabolite changes in TCA cycle, fatty acid and amino acid metabolism, and affected enzymatic pathways in DKD clinical and preclinical studies. MPC = Mitochondrial pyruvate carrier; PDH = pyruvate dehydrogenase complex; IDH = isocitric dehydrogenase; α-KGDH = alpha ketoglutarate dehydrogenase. Metabolites associated with clinical studies are indicated with red arrows and preclinical studies with blue arrows.